nodes	percent_of_prediction	percent_of_DWPC	metapath
Bisacodyl—Anorectal discomfort—Acitretin—psoriasis	0.0361	0.0402	CcSEcCtD
Bisacodyl—Abdominal cramps—Calcitriol—psoriasis	0.0328	0.0366	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—HCAR2—psoriasis	0.0174	0.169	CbGpPWpGaD
Bisacodyl—Dehydration—Calcitriol—psoriasis	0.015	0.0167	CcSEcCtD
Bisacodyl—Hypersensitivity—Calcipotriol—psoriasis	0.0147	0.0164	CcSEcCtD
Bisacodyl—Immune system disorder—Fluocinonide—psoriasis	0.0143	0.0159	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	0.0138	0.134	CbGpPWpGaD
Bisacodyl—Angioedema—Beclomethasone—psoriasis	0.0127	0.0142	CcSEcCtD
Bisacodyl—Colitis—Mycophenolic acid—psoriasis	0.0124	0.0139	CcSEcCtD
Bisacodyl—Anaphylactic shock—Beclomethasone—psoriasis	0.0113	0.0126	CcSEcCtD
Bisacodyl—Nervous system disorder—Fluocinonide—psoriasis	0.011	0.0123	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—HCAR2—psoriasis	0.0105	0.102	CbGpPWpGaD
Bisacodyl—Muscle spasms—Methoxsalen—psoriasis	0.0104	0.0116	CcSEcCtD
Bisacodyl—Colitis—Mycophenolate mofetil—psoriasis	0.00982	0.011	CcSEcCtD
Bisacodyl—Hypersensitivity—Clobetasol propionate—psoriasis	0.00918	0.0102	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—CCL20—psoriasis	0.00905	0.0877	CbGpPWpGaD
Bisacodyl—Immune system disorder—Acitretin—psoriasis	0.00894	0.00997	CcSEcCtD
Bisacodyl—Dehydration—Mycophenolic acid—psoriasis	0.00875	0.00976	CcSEcCtD
Bisacodyl—Malnutrition—Fluocinolone Acetonide—psoriasis	0.00859	0.00958	CcSEcCtD
Bisacodyl—Cramp muscle—Mycophenolic acid—psoriasis	0.00847	0.00945	CcSEcCtD
Bisacodyl—Muscle spasms—Acitretin—psoriasis	0.00828	0.00924	CcSEcCtD
Bisacodyl—Hypersensitivity—Fluocinonide—psoriasis	0.00828	0.00923	CcSEcCtD
Bisacodyl—Anaphylactic shock—Calcitriol—psoriasis	0.00791	0.00881	CcSEcCtD
Bisacodyl—Angioedema—Acitretin—psoriasis	0.00787	0.00878	CcSEcCtD
Bisacodyl—Headache—Clobetasol propionate—psoriasis	0.0078	0.0087	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Methoxsalen—psoriasis	0.00766	0.00854	CcSEcCtD
Bisacodyl—Dizziness—Beclomethasone—psoriasis	0.0075	0.00836	CcSEcCtD
Bisacodyl—Dizziness—Fluocinonide—psoriasis	0.00743	0.00829	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	0.00719	0.0697	CbGpPWpGaD
Bisacodyl—Headache—Beclomethasone—psoriasis	0.0071	0.00792	CcSEcCtD
Bisacodyl—Headache—Fluocinonide—psoriasis	0.00704	0.00785	CcSEcCtD
Bisacodyl—Dehydration—Mycophenolate mofetil—psoriasis	0.00691	0.0077	CcSEcCtD
Bisacodyl—Nervous system disorder—Fluocinolone Acetonide—psoriasis	0.00688	0.00767	CcSEcCtD
Bisacodyl—Cramp muscle—Cyclosporine—psoriasis	0.00685	0.00764	CcSEcCtD
Bisacodyl—Nausea—Beclomethasone—psoriasis	0.00674	0.00751	CcSEcCtD
Bisacodyl—Hypersensitivity—Methoxsalen—psoriasis	0.00653	0.00729	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Calcitriol—psoriasis	0.00646	0.00721	CcSEcCtD
Bisacodyl—Abdominal discomfort—Cyclosporine—psoriasis	0.00631	0.00703	CcSEcCtD
Bisacodyl—Abdominal pain—Calcitriol—psoriasis	0.00625	0.00697	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Acitretin—psoriasis	0.00607	0.00677	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Fluocinolone Acetonide—psoriasis	0.00605	0.00675	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—HCAR2—psoriasis	0.00596	0.0578	CbGpPWpGaD
Bisacodyl—Dizziness—Methoxsalen—psoriasis	0.00587	0.00654	CcSEcCtD
Bisacodyl—Hypersensitivity—Calcitriol—psoriasis	0.00582	0.00649	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Acitretin—psoriasis	0.00575	0.00641	CcSEcCtD
Bisacodyl—Malnutrition—Mycophenolic acid—psoriasis	0.00567	0.00632	CcSEcCtD
Bisacodyl—Abdominal pain—Acitretin—psoriasis	0.00556	0.0062	CcSEcCtD
Bisacodyl—Headache—Methoxsalen—psoriasis	0.00556	0.0062	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—CCL20—psoriasis	0.00548	0.0531	CbGpPWpGaD
Bisacodyl—Muscle spasms—Mycophenolic acid—psoriasis	0.00545	0.00607	CcSEcCtD
Bisacodyl—Nervous system disorder—Hydroxyurea—psoriasis	0.00541	0.00604	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—HCAR2—psoriasis	0.00541	0.0525	CbGpPWpGaD
Bisacodyl—Diarrhoea—Calcitriol—psoriasis	0.00541	0.00603	CcSEcCtD
Bisacodyl—Nausea—Methoxsalen—psoriasis	0.00527	0.00587	CcSEcCtD
Bisacodyl—Hypersensitivity—Acitretin—psoriasis	0.00518	0.00578	CcSEcCtD
Bisacodyl—Hypersensitivity—Fluocinolone Acetonide—psoriasis	0.00517	0.00576	CcSEcCtD
Bisacodyl—Syncope—Mycophenolic acid—psoriasis	0.00508	0.00567	CcSEcCtD
Bisacodyl—Vomiting—Calcitriol—psoriasis	0.00503	0.0056	CcSEcCtD
Bisacodyl—Loss of consciousness—Mycophenolic acid—psoriasis	0.00498	0.00555	CcSEcCtD
Bisacodyl—Headache—Calcitriol—psoriasis	0.00495	0.00552	CcSEcCtD
Bisacodyl—Diarrhoea—Acitretin—psoriasis	0.00481	0.00536	CcSEcCtD
Bisacodyl—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.0048	0.00535	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.00477	0.00531	CcSEcCtD
Bisacodyl—Nausea—Calcitriol—psoriasis	0.0047	0.00524	CcSEcCtD
Bisacodyl—Dizziness—Acitretin—psoriasis	0.00465	0.00519	CcSEcCtD
Bisacodyl—Dizziness—Fluocinolone Acetonide—psoriasis	0.00464	0.00517	CcSEcCtD
Bisacodyl—Malnutrition—Cyclosporine—psoriasis	0.00458	0.00511	CcSEcCtD
Bisacodyl—Shock—Mycophenolic acid—psoriasis	0.00455	0.00507	CcSEcCtD
Bisacodyl—Nervous system disorder—Mycophenolic acid—psoriasis	0.00453	0.00506	CcSEcCtD
Bisacodyl—Malnutrition—Mycophenolate mofetil—psoriasis	0.00447	0.00499	CcSEcCtD
Bisacodyl—Vomiting—Acitretin—psoriasis	0.00447	0.00499	CcSEcCtD
Bisacodyl—Vomiting—Fluocinolone Acetonide—psoriasis	0.00446	0.00497	CcSEcCtD
Bisacodyl—Muscle spasms—Cyclosporine—psoriasis	0.00441	0.00491	CcSEcCtD
Bisacodyl—Headache—Acitretin—psoriasis	0.00441	0.00491	CcSEcCtD
Bisacodyl—Headache—Fluocinolone Acetonide—psoriasis	0.00439	0.0049	CcSEcCtD
Bisacodyl—Muscle spasms—Mycophenolate mofetil—psoriasis	0.0043	0.00479	CcSEcCtD
Bisacodyl—Immune system disorder—Hydrocortisone—psoriasis	0.00423	0.00471	CcSEcCtD
Bisacodyl—Angioedema—Cyclosporine—psoriasis	0.00419	0.00467	CcSEcCtD
Bisacodyl—Nausea—Acitretin—psoriasis	0.00418	0.00466	CcSEcCtD
Bisacodyl—Nausea—Fluocinolone Acetonide—psoriasis	0.00417	0.00464	CcSEcCtD
Bisacodyl—Angioedema—Mycophenolate mofetil—psoriasis	0.00409	0.00456	CcSEcCtD
Bisacodyl—Malnutrition—Hydrocortisone—psoriasis	0.00407	0.00454	CcSEcCtD
Bisacodyl—Hypersensitivity—Hydroxyurea—psoriasis	0.00407	0.00454	CcSEcCtD
Bisacodyl—Syncope—Mycophenolate mofetil—psoriasis	0.00401	0.00447	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.00399	0.00445	CcSEcCtD
Bisacodyl—Loss of consciousness—Mycophenolate mofetil—psoriasis	0.00393	0.00438	CcSEcCtD
Bisacodyl—Angioedema—Prednisolone—psoriasis	0.00381	0.00425	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Mycophenolic acid—psoriasis	0.00378	0.00422	CcSEcCtD
Bisacodyl—Diarrhoea—Hydroxyurea—psoriasis	0.00378	0.00421	CcSEcCtD
Bisacodyl—Anaphylactic shock—Cyclosporine—psoriasis	0.00374	0.00417	CcSEcCtD
Bisacodyl—Syncope—Prednisolone—psoriasis	0.00374	0.00417	CcSEcCtD
Bisacodyl—Angioedema—Hydrocortisone—psoriasis	0.00372	0.00415	CcSEcCtD
Bisacodyl—Nervous system disorder—Cyclosporine—psoriasis	0.00367	0.00409	CcSEcCtD
Bisacodyl—Loss of consciousness—Prednisolone—psoriasis	0.00367	0.00409	CcSEcCtD
Bisacodyl—Abdominal pain—Mycophenolic acid—psoriasis	0.00366	0.00408	CcSEcCtD
Bisacodyl—Syncope—Hydrocortisone—psoriasis	0.00365	0.00407	CcSEcCtD
Bisacodyl—Dizziness—Hydroxyurea—psoriasis	0.00365	0.00407	CcSEcCtD
Bisacodyl—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.00365	0.00407	CcSEcCtD
Bisacodyl—Shock—Mycophenolate mofetil—psoriasis	0.00359	0.004	CcSEcCtD
Bisacodyl—Loss of consciousness—Hydrocortisone—psoriasis	0.00358	0.00399	CcSEcCtD
Bisacodyl—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.00358	0.00399	CcSEcCtD
Bisacodyl—Vomiting—Hydroxyurea—psoriasis	0.00351	0.00391	CcSEcCtD
Bisacodyl—Angioedema—Triamcinolone—psoriasis	0.00351	0.00391	CcSEcCtD
Bisacodyl—Abdominal discomfort—Methotrexate—psoriasis	0.00349	0.00389	CcSEcCtD
Bisacodyl—Headache—Hydroxyurea—psoriasis	0.00346	0.00386	CcSEcCtD
Bisacodyl—Syncope—Triamcinolone—psoriasis	0.00344	0.00384	CcSEcCtD
Bisacodyl—Anaphylactic shock—Prednisolone—psoriasis	0.0034	0.0038	CcSEcCtD
Bisacodyl—Loss of consciousness—Triamcinolone—psoriasis	0.00337	0.00376	CcSEcCtD
Bisacodyl—Shock—Prednisolone—psoriasis	0.00335	0.00373	CcSEcCtD
Bisacodyl—Anaphylactic shock—Hydrocortisone—psoriasis	0.00332	0.00371	CcSEcCtD
Bisacodyl—Nausea—Hydroxyurea—psoriasis	0.00328	0.00366	CcSEcCtD
Bisacodyl—Shock—Hydrocortisone—psoriasis	0.00327	0.00365	CcSEcCtD
Bisacodyl—Nervous system disorder—Hydrocortisone—psoriasis	0.00326	0.00364	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Cyclosporine—psoriasis	0.00323	0.0036	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—HCAR2—psoriasis	0.0032	0.031	CbGpPWpGaD
Bisacodyl—Angioedema—Betamethasone—psoriasis	0.00318	0.00355	CcSEcCtD
Bisacodyl—Angioedema—Dexamethasone—psoriasis	0.00318	0.00355	CcSEcCtD
Bisacodyl—Diarrhoea—Mycophenolic acid—psoriasis	0.00316	0.00353	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.00315	0.00351	CcSEcCtD
Bisacodyl—Immune system disorder—Prednisone—psoriasis	0.00315	0.00351	CcSEcCtD
Bisacodyl—Anaphylactic shock—Triamcinolone—psoriasis	0.00313	0.00349	CcSEcCtD
Bisacodyl—Syncope—Dexamethasone—psoriasis	0.00312	0.00348	CcSEcCtD
Bisacodyl—Syncope—Betamethasone—psoriasis	0.00312	0.00348	CcSEcCtD
Bisacodyl—GPR55—GPCR downstream signaling—CCL20—psoriasis	0.00309	0.03	CbGpPWpGaD
Bisacodyl—Shock—Triamcinolone—psoriasis	0.00308	0.00343	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Cyclosporine—psoriasis	0.00306	0.00341	CcSEcCtD
Bisacodyl—Loss of consciousness—Dexamethasone—psoriasis	0.00306	0.00341	CcSEcCtD
Bisacodyl—Loss of consciousness—Betamethasone—psoriasis	0.00306	0.00341	CcSEcCtD
Bisacodyl—Dizziness—Mycophenolic acid—psoriasis	0.00306	0.00341	CcSEcCtD
Bisacodyl—Malnutrition—Prednisone—psoriasis	0.00303	0.00338	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	0.00298	0.00333	CcSEcCtD
Bisacodyl—Abdominal pain—Cyclosporine—psoriasis	0.00296	0.0033	CcSEcCtD
Bisacodyl—Vomiting—Mycophenolic acid—psoriasis	0.00294	0.00328	CcSEcCtD
Bisacodyl—Headache—Mycophenolic acid—psoriasis	0.0029	0.00323	CcSEcCtD
Bisacodyl—Abdominal pain—Mycophenolate mofetil—psoriasis	0.00288	0.00322	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.00287	0.0032	CcSEcCtD
Bisacodyl—Anaphylactic shock—Dexamethasone—psoriasis	0.00284	0.00317	CcSEcCtD
Bisacodyl—Anaphylactic shock—Betamethasone—psoriasis	0.00284	0.00317	CcSEcCtD
Bisacodyl—GPR55—Signaling by GPCR—CCL20—psoriasis	0.00281	0.0273	CbGpPWpGaD
Bisacodyl—Shock—Betamethasone—psoriasis	0.00279	0.00312	CcSEcCtD
Bisacodyl—Shock—Dexamethasone—psoriasis	0.00279	0.00312	CcSEcCtD
Bisacodyl—Nervous system disorder—Betamethasone—psoriasis	0.00279	0.00311	CcSEcCtD
Bisacodyl—Nervous system disorder—Dexamethasone—psoriasis	0.00279	0.00311	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—TAGAP—psoriasis	0.00277	0.0269	CbGpPWpGaD
Bisacodyl—Angioedema—Prednisone—psoriasis	0.00277	0.00309	CcSEcCtD
Bisacodyl—Hypersensitivity—Cyclosporine—psoriasis	0.00276	0.00307	CcSEcCtD
Bisacodyl—Nausea—Mycophenolic acid—psoriasis	0.00275	0.00306	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Hydrocortisone—psoriasis	0.00272	0.00303	CcSEcCtD
Bisacodyl—Syncope—Prednisone—psoriasis	0.00272	0.00303	CcSEcCtD
Bisacodyl—Hypersensitivity—Mycophenolate mofetil—psoriasis	0.00269	0.003	CcSEcCtD
Bisacodyl—Loss of consciousness—Prednisone—psoriasis	0.00266	0.00297	CcSEcCtD
Bisacodyl—Immune system disorder—Methotrexate—psoriasis	0.00263	0.00293	CcSEcCtD
Bisacodyl—Abdominal pain—Hydrocortisone—psoriasis	0.00263	0.00293	CcSEcCtD
Bisacodyl—Diarrhoea—Cyclosporine—psoriasis	0.00256	0.00285	CcSEcCtD
Bisacodyl—Malnutrition—Methotrexate—psoriasis	0.00253	0.00282	CcSEcCtD
Bisacodyl—Hypersensitivity—Prednisolone—psoriasis	0.00251	0.0028	CcSEcCtD
Bisacodyl—Diarrhoea—Mycophenolate mofetil—psoriasis	0.0025	0.00278	CcSEcCtD
Bisacodyl—Dizziness—Cyclosporine—psoriasis	0.00247	0.00276	CcSEcCtD
Bisacodyl—Anaphylactic shock—Prednisone—psoriasis	0.00247	0.00276	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Dexamethasone—psoriasis	0.00245	0.00273	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Betamethasone—psoriasis	0.00245	0.00273	CcSEcCtD
Bisacodyl—Hypersensitivity—Hydrocortisone—psoriasis	0.00245	0.00273	CcSEcCtD
Bisacodyl—GPR55—G alpha (i) signalling events—CXCL8—psoriasis	0.00244	0.0237	CbGpPWpGaD
Bisacodyl—Shock—Prednisone—psoriasis	0.00243	0.00271	CcSEcCtD
Bisacodyl—Nervous system disorder—Prednisone—psoriasis	0.00243	0.0027	CcSEcCtD
Bisacodyl—Dizziness—Mycophenolate mofetil—psoriasis	0.00241	0.00269	CcSEcCtD
Bisacodyl—Vomiting—Cyclosporine—psoriasis	0.00238	0.00265	CcSEcCtD
Bisacodyl—Headache—Cyclosporine—psoriasis	0.00234	0.00261	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Dexamethasone—psoriasis	0.00232	0.00259	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Betamethasone—psoriasis	0.00232	0.00259	CcSEcCtD
Bisacodyl—Vomiting—Mycophenolate mofetil—psoriasis	0.00232	0.00259	CcSEcCtD
Bisacodyl—Hypersensitivity—Triamcinolone—psoriasis	0.00231	0.00257	CcSEcCtD
Bisacodyl—Headache—Mycophenolate mofetil—psoriasis	0.00229	0.00255	CcSEcCtD
Bisacodyl—Diarrhoea—Hydrocortisone—psoriasis	0.00227	0.00254	CcSEcCtD
Bisacodyl—Dizziness—Prednisolone—psoriasis	0.00225	0.00251	CcSEcCtD
Bisacodyl—Abdominal pain—Dexamethasone—psoriasis	0.00225	0.0025	CcSEcCtD
Bisacodyl—Abdominal pain—Betamethasone—psoriasis	0.00225	0.0025	CcSEcCtD
Bisacodyl—Nausea—Cyclosporine—psoriasis	0.00222	0.00248	CcSEcCtD
Bisacodyl—Dizziness—Hydrocortisone—psoriasis	0.0022	0.00245	CcSEcCtD
Bisacodyl—Nausea—Mycophenolate mofetil—psoriasis	0.00217	0.00242	CcSEcCtD
Bisacodyl—Headache—Prednisolone—psoriasis	0.00213	0.00238	CcSEcCtD
Bisacodyl—Vomiting—Hydrocortisone—psoriasis	0.00211	0.00236	CcSEcCtD
Bisacodyl—Headache—Hydrocortisone—psoriasis	0.00208	0.00232	CcSEcCtD
Bisacodyl—Dizziness—Triamcinolone—psoriasis	0.00207	0.00231	CcSEcCtD
Bisacodyl—Anaphylactic shock—Methotrexate—psoriasis	0.00207	0.00231	CcSEcCtD
Bisacodyl—Nervous system disorder—Methotrexate—psoriasis	0.00203	0.00226	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Prednisone—psoriasis	0.00202	0.00226	CcSEcCtD
Bisacodyl—Nausea—Prednisolone—psoriasis	0.00202	0.00225	CcSEcCtD
Bisacodyl—Vomiting—Triamcinolone—psoriasis	0.00199	0.00222	CcSEcCtD
Bisacodyl—Nausea—Hydrocortisone—psoriasis	0.00197	0.0022	CcSEcCtD
Bisacodyl—Headache—Triamcinolone—psoriasis	0.00196	0.00219	CcSEcCtD
Bisacodyl—Abdominal pain—Prednisone—psoriasis	0.00196	0.00218	CcSEcCtD
Bisacodyl—Diarrhoea—Betamethasone—psoriasis	0.00194	0.00217	CcSEcCtD
Bisacodyl—Diarrhoea—Dexamethasone—psoriasis	0.00194	0.00217	CcSEcCtD
Bisacodyl—GPR55—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.00194	0.0188	CbGpPWpGaD
Bisacodyl—Dizziness—Betamethasone—psoriasis	0.00188	0.00209	CcSEcCtD
Bisacodyl—Dizziness—Dexamethasone—psoriasis	0.00188	0.00209	CcSEcCtD
Bisacodyl—Nausea—Triamcinolone—psoriasis	0.00186	0.00207	CcSEcCtD
Bisacodyl—Hypersensitivity—Prednisone—psoriasis	0.00182	0.00203	CcSEcCtD
Bisacodyl—Vomiting—Dexamethasone—psoriasis	0.00181	0.00201	CcSEcCtD
Bisacodyl—Vomiting—Betamethasone—psoriasis	0.00181	0.00201	CcSEcCtD
Bisacodyl—Gastrointestinal disorder—Methotrexate—psoriasis	0.00178	0.00199	CcSEcCtD
Bisacodyl—Headache—Betamethasone—psoriasis	0.00178	0.00198	CcSEcCtD
Bisacodyl—Headache—Dexamethasone—psoriasis	0.00178	0.00198	CcSEcCtD
Bisacodyl—Diarrhoea—Prednisone—psoriasis	0.00169	0.00189	CcSEcCtD
Bisacodyl—Gastrointestinal pain—Methotrexate—psoriasis	0.00169	0.00188	CcSEcCtD
Bisacodyl—Nausea—Betamethasone—psoriasis	0.00169	0.00188	CcSEcCtD
Bisacodyl—Nausea—Dexamethasone—psoriasis	0.00169	0.00188	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—CCL20—psoriasis	0.00166	0.0161	CbGpPWpGaD
Bisacodyl—Dizziness—Prednisone—psoriasis	0.00164	0.00182	CcSEcCtD
Bisacodyl—Abdominal pain—Methotrexate—psoriasis	0.00163	0.00182	CcSEcCtD
Bisacodyl—Vomiting—Prednisone—psoriasis	0.00157	0.00175	CcSEcCtD
Bisacodyl—Headache—Prednisone—psoriasis	0.00155	0.00173	CcSEcCtD
Bisacodyl—Hypersensitivity—Methotrexate—psoriasis	0.00152	0.0017	CcSEcCtD
Bisacodyl—GPR55—GPCR ligand binding—CXCL8—psoriasis	0.00148	0.0143	CbGpPWpGaD
Bisacodyl—Nausea—Prednisone—psoriasis	0.00147	0.00164	CcSEcCtD
Bisacodyl—Diarrhoea—Methotrexate—psoriasis	0.00141	0.00158	CcSEcCtD
Bisacodyl—Dizziness—Methotrexate—psoriasis	0.00137	0.00152	CcSEcCtD
Bisacodyl—Vomiting—Methotrexate—psoriasis	0.00131	0.00147	CcSEcCtD
Bisacodyl—Headache—Methotrexate—psoriasis	0.0013	0.00144	CcSEcCtD
Bisacodyl—Nausea—Methotrexate—psoriasis	0.00123	0.00137	CcSEcCtD
Bisacodyl—GPR55—Signaling Pathways—SOCS1—psoriasis	0.000914	0.00887	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—TYK2—psoriasis	0.000872	0.00845	CbGpPWpGaD
Bisacodyl—GPR55—GPCR downstream signaling—CXCL8—psoriasis	0.000836	0.00811	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—CXCL8—psoriasis	0.000759	0.00736	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—LEP—psoriasis	0.000675	0.00654	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—APOE—psoriasis	0.000675	0.00654	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—NFKBIA—psoriasis	0.000629	0.0061	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—TYK2—psoriasis	0.000515	0.00499	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—CXCL8—psoriasis	0.000448	0.00435	CbGpPWpGaD
Bisacodyl—GPR55—Signaling by GPCR—IL6—psoriasis	0.000426	0.00413	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—JUN—psoriasis	0.000417	0.00404	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—NFKB1—psoriasis	0.000401	0.00389	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—VEGFA—psoriasis	0.000364	0.00353	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—STAT3—psoriasis	0.000361	0.0035	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—TP53—psoriasis	0.000275	0.00267	CbGpPWpGaD
Bisacodyl—GPR55—Signaling Pathways—IL6—psoriasis	0.000252	0.00244	CbGpPWpGaD
